Select Bibliography

Select Bibliography

Filter by any of these (after searching):

Federally Funded Research

There are 213 items

Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB 80802 (Alliance) (C8)

DOI

Google Scholar

Abou-Alfa, Ghassan K. , Shi, Qian , Knox, Jennifer J. ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80802

Long-term cardiac safety analysis of NCCTG (Alliance) N9831 adjuvant trastuzumab (H) trial.

Google Scholar

Advani, Pooja Prem , Ballman, Karla V. , Dockter, Travis J. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Long-Term-Followup Analysis - Breast - N9831

A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: an Alliance Foundation trial (AFT-19)

DOI

Google Scholar

Aggarwal, Rahul , Eggener, Scott , Chen, Ronald , Heller, Glenn ... - ASCO - J Clin Oncol - 2018

Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - GU - AFT-19

Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM) CALGB 100104 (Alliance)

Google Scholar

Ailawadhi, Sikander , McCarthy, Philip L. , Holstein, Sarah A. ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Transplant - CALGB-100104 , E4A03 , MM-002 , MM-009

Efficacy and toxicity of cetuximab (C225) plus mFOLOFX6 in patients (pts) with nonoptimally resectable, colorectal metastases (MCRC) confined to the liver

Google Scholar

Alberts, S. R. , Donohue, J. H. , Mahoney, M. R. , Nelson, G. D. ... - ASCO - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N014A

Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147.

Google Scholar

Alberts, S. R. , Thibodeau, S. N. , Sargent, D. J. , Mahoney, M. R. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0147

Randomized phase II trial of extended versus standard neoadjuvant therapy for esophageal cancer, NCCTG (Alliance) trial N0849

Google Scholar

Alberts, S. , Soori, G. , Shi, Q. , Wigle, D. , Sticca, R. , Miller, R. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Preliminary Analysis - GI - N0849

Validating RNAseq-Signatures of Vorinostat (VOR) Sensitivity and Resistance in Patients with Newly Diagnosed Glioblastoma (GBM) Treated with VOR, Temozolomide and Radiation Therapy From Alliance N0874/ABTC-0902.

Google Scholar

Anderson, S. Keith , Miller, C. Ryan , Sarkaria, Jann N. ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary Endpoint - Primary Analysis - Neuro-Onc - N0874 , ABTC-0902

Outcomes following adjuvant treatment (AT) for colon cancer (CC) 1978-1995 versus 1996-2007: Impact on recurrence rate, time from recurrence to death (TRD), and overall survival (OS) -- Findings from the ACCENT dataset.

Google Scholar

Andre, T. , Shi, Q. , Yothers, G. , Bot, B. , Haller, D. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0441

Comparison Between Clinician- and Patient-Reporting of Baseline (BL) and Post-BL Symptomatic Toxicities in Cancer Cooperative Group Clinical Trials (NCCTG N0591 [Alliance])

Google Scholar

Atkinson, Thomas M. , Satele, Daniel V. , Sloan, Jeff A. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary Endpoint - Primary Analysis - Health Outcome - N0591

Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS) CALGB 100104 (Alliance)

Google Scholar

Attal, Michel , Palumbo, Antonio , Holstein, Sarah ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Myeloma - CALGB-100104

Treatment of older patients with de novo acute myeloid leukemia (AML) with one or more postremission chemotherapy courses: Analysis of four CALGB studies

Google Scholar

Baer, M. R. , George, S. L. , Sanford, B. L. , Stone, R. M. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Leukemia - C8525 , CALGB-10201 , CALGB-8923 , CALGB-9720

Impact of vaginal dehydroepiandosterone (DHEA) on vaginal symptoms in female cancer survivors: Trial N10C1 (Alliance)

Google Scholar

Barton, Debra L. , Sloan, Jeff A. , Shuster, Lynne T , Gill, Paula ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N10C1

Randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202).

Google Scholar

Bergsland, Emily K. , Mahoney, Michelle R. , Asmis, Timothy R. ... - ASCO - J Clin Oncol - 2019

Abstract - Primary Endpoint - Primary Analysis - GI - A021202

Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581

Google Scholar

Bertagnolli, M. M. , Niedzwiecki, D. , Hall, M. , Jewell, S. D. ... - ASCO - J. Clin. Oncol. - 2009

Abstract - Secondary Endpoint - Primary Analysis - GI - C9581

Meta-analyses of 22 randomized trials assessing the influence of chemotherapy in advanced/recurrent gastric cancer.

Google Scholar

Bleiberg, H. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - NCCTG-79-41-51 , NCCTG-83-41-51

Factors associated with lymphedema in patients/women with node positive breast cancer treated with neoadjuvant chemotherapy and axillary dissection on a prospective clinical trial (Alliance) ACOSOG Z1071

DOI

Google Scholar

Boughey, Judy C. , Ballman, Karla , McCall, Linda , Kuerer, Henry ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Effect of the use of immediate reconstruction on the rates of bilateral mastectomy and adjuvant radiation therapy use in women with node-positive breast cancer treated with neoadjuvant chemotherapy on ACOSOG Z1071 (Alliance).

Google Scholar

Boughey, Judy C. , McCall, Linda , Haffty, Bruce , Buchholz, Tom ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

NCCTG N0574 (Alliance): A Phase III Randomized Trial of Whole Brain Radiation Therapy (WBRT) in Addition to Radiosurgery (SRS) in Patients with 1 to 3 Brain Metastases

Google Scholar

Brown, Paul D. , Asher, Anthony L. , Ballman, Karla V. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0574

ACOSOG Z1041 (Alliance): Definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC -> P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T -> FEC+T) in HER2+ operable breast cancer

Google Scholar

Buzdar, A. , Suman, V. , Meric-Bernstam, F. , Leitch, M. , Ellis, M. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041

What is the added value of actual tumor measurements (TM) in predicting overall survival (OS)? The North Central Cancer Treatment Group (NCCTG) findings

Google Scholar

Campbell, M. E. , Mandrekar, S. J. , Hillman, S. L. , Goldberg, R. M. ... - ASCO - J. Clin. Oncol. - 2008

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - NCCTG-N0026 , NCCTG-N9741

Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).

Google Scholar

Carey, Lisa A. , Barry, William Thomas , Pitcher, Brandy ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-40601

Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer

Google Scholar

Carey, Lisa A. , Berry, Donald A. , Ollila, David , Harris, Lyndsay ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Breast - C40601

Patient satisfaction with participation in phase II/III NCCTG clinical trials: Was it worth it? (N0392)

Google Scholar

Chauhan, C. , Atherton, P. J. , Satele, D. , Dueck, A. C. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Primary Endpoint - Primary Analysis - Health Outcome - NCCTG-N0392

Quality-adjusted time without symptoms or toxicity (Q-TWiST): analysis of cabozantinib versus sunitinib in patients with advanced renal cell carcinoma of intermediate or poor risk (Alliance A031203)

Google Scholar

Chen, RC , Feuilly, M , Meng, J , Lister, J , Marteau, F , Morris, M ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - A031203

Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials

Google Scholar

Chumsri, Saranya , Serie, Daniel , Mashadi-Hossein, Afshin ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N9831

Correlation of high p95HER2:HER2 ratio with poor outcome in two phase II clinical trials of trastuzumab-treated HER2-positive metastatic breast cancer.

Google Scholar

Chumsri, Saranya , Sperinde, Jeff , Liu, Heshan , Gligorov, Joseph ... - ASCO - J Clin Oncol - 2016

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N0337 , N98-32-52

Combination trastuzumab and chemotherapy to induce immunity to multiple tumor antigens in patients with HER2-positive metastatic breast cancer: NCCTG (Alliance) studies N0337 and N98-32-52

Google Scholar

Clynes, R. , Knutson, K. L. , Ballman, K. , Erskine, C. L. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N0337 , N98-32-52

Alliance A091103: A multicenter phase II study of the angiopoietin-1 and -2 peptibody trebananib (AMG386) for the treatment of angiosarcoma (AS).

Google Scholar

D'Angelo, Sandra P. , Mahoney, Michelle R. , Van Tine, Brian Andrew ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - Experimental - A091103

Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001

Google Scholar

Dematteo, R. , Owzar, K. , Maki, R. , Pisters, P. , Blackstein, M. ... - ASCO - ASCO Annual Meeting - 2007

Abstract - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z9001

Loss of p27 expression and response to neoadjuvant chemotherapy: Results from the I-SPY Trial (CALGB150007/150012, ACRIN6657)

Google Scholar

Demichele, A. , Dunn, L. , Gimotty, P. , Livasy, C. , Perou, C. ... - ASCO - J Clin Oncol - 2009

Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007

Phase III Trial Evaluating the Addition of Bevacizumab to Letrozole As First-line Endocrine Therapy for Treatment of Hormone-receptor Positive Advanced Breast Cancer: CALGB 40503 (Alliance)

Google Scholar

Dickler, Maura N. , Barry, William Thomas ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - Breast - CALGB-40503

Alliance A091102: Phase II study of MLN8237 (alisertib) in advanced/metastatic sarcoma

Google Scholar

Dickson, Mark Andrew , Mahoney, Michelle R. , Marchello, Benjamin T. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Experimental - A091102

Randomized phase 2 study of maintenance pemetrexed versus observation for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB/Alliance) 30901

DOI

Google Scholar

Dudek, Arkadiusz Z. , Wang, Xiaofei , Gu, Lin , Stinchcombe, Thomas ... - ASCO - J Clin Oncol - 2019

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30901

Calibrating clinically significant effects in survival and response endpoints in cancer clinical trials.

Google Scholar

Dueck, A. , Sargent, D. , Novotny, P. , Decker, P. , Nelson, H. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Health Outcome - N0591

Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D).

Google Scholar

Dueck, Amylou C. , Hillman, David W. , Kottschade, Lisa A. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N063D

A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401)

Google Scholar

D’Angelo, Sandra P. , Mahoney, Michelle R. , Van Tine, Brian ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Primary Endpoint - Primary Analysis - Experimental - A091401

CALGB 90203 (Alliance): Radical Prostatectomy with or without neoadjuvant chemohormonal therapy in men with clinically localized, high risk prostate cancer

DOI

Google Scholar

Eastham, J.A. , Heller, G. , Halabi, S. , Monk, J. P. , Beltran, H. ... - ASCO - J. Clin. Oncol. - 2019

Abstract - Primary Endpoint - Primary Analysis - GU - CALGB-90203

Nut Consumption and Survival in Stage III Colon Cancer Patients: Results from CALGB 89803 (Alliance)

DOI

Google Scholar

Fadelu, Temidayo , Sui Zhang , Donna Niedzwiecki , Xing Ye ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-89803

Causal modeling of CALGB 80405 (Alliance) identifies network drivers of metastatic colorectal cancer (CRC)

Google Scholar

Federico Innocenti , Heinz-Josef Lenz , Jeffrey Meyerhardt ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405

ECOG score analysis as a proxy for health-related quality of life assessment in patients with poor or intermediate risk metastatic renal cell carcinoma from the CABOSUN trial (Alliance A031203)

Google Scholar

Feldman, D , Feuilly, M , Meng, J , Lister, J , Marteau, F , Morris, MJ ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - A031203

Genomic predictive biomarkers to anti-HER2 targeted therapies: a combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials

DOI

Google Scholar

Fernandez-Martinez, Aranzazu , Tanioka, Maki , Fan, Cheng ... - ASCO - J. Clin. Oncol. - 2019

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - CALGB-40601

Impact of brachytherapy on local recurrence after sublobar resection: Results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small cell lung cancer (NSCLC)

Google Scholar

Fernando, H. , Landreneau, R. , Mandrekar, S. , Nichols, F. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4032

Comparative nocebo findings in older patients enrolled in cancer therapeutic trials: observations from a 446-patient cohort (Alliance A151602)

Google Scholar

Foster, Jared C. , Le-Rademacher, Jennifer G. ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Primary Endpoint - Primary Analysis - Older Adult - A151602 , ACOSOG-Z9001 , NCCTG-97-24-51

Accrual of Older Breast Cancer Patients to Alliance Systemic Therapy Protocols over Time: Alliance A151527 (Multiple)

Google Scholar

Freedman, Rachel A , Seisler, Drew K. , Foster, Jared C. ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Primary Endpoint - Comprehensive Analysis - Older Adult - A151527 , ACOSOG-Z1031 , ACOSOG-Z1041 , C8541 , C9344 , C9741 , CALGB-40101 , CALGB-40302 , CALGB-40502 , CALGB-40503 , CALGB-40601 , CALGB-40603 , CALGB-49907 , CALGB-9342 , CALGB-9840 , N89-30-52 , N9831

Postoperative adjuvant chemoradiation for gastric or gastroesophageal (GE) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (RT): Results from Intergroup trial CALGB 80101

Google Scholar

Fuchs, C. S. , Tepper, J. E. , Niedzwiecki, D. , Hollis, D. R. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80101

Statistical modeling of CALGB 80405 (Alliance) to identify influential factors in metastatic colorectal cancer (CRC) dependent on primary tumor side.

Google Scholar

Furchtgott, Leon , Swanson, David , Hayete, Boris , Khalil, Iya ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405

Phase I/II trial of vorinostat combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (N0874-ABTC0902, Alliance): Final results of the phase I trial

Google Scholar

Galanis, E. , Sarkaria, J. , Anderson, K. , Wu, W. , Jaeckle, K. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0874

NCCTG N0872 (Alliance): A Randomized Placebo-Controlled Phase II Trial of Bevacizumab Plus Dasatinib in Patients with Recurrent Glioblastoma (GBM)

Google Scholar

Galanis, Evanthia , Anderson, S. Keith , Anastasiadis, Panagiotis Z. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0872

NCCTG N1174: Phase I/Comparative Randomized Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma Multiforme (Alliance)

Google Scholar

Galanis, Evanthia , Anderson, S. Keith , Butowski, Nicholas ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N1174

Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902)

Google Scholar

Galanis, Evanthia , Anderson, S. Keith , Miller, C. Ryan ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0874

Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance)

Google Scholar

George, Daniel.J. , Halabi, Susan , Nixon, Andrew B. , Starr, Mark D. ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-90206

Ten-Year Survival Results of ACOSOG Z0011 (Alliance)

Google Scholar

Giuliano, Armando E. , Hunt, Kelly K. , Ballman, Karla. V. ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary Endpoint - Long-Term-Followup Analysis - Breast - ACOSOG-Z0011

Variability of Pelvic MRI Performance in a Prospective Multicenter Rectal Cancer Trial NCCTG N1048 (Alliance)

Google Scholar

Gollub, Marc J. , Shi, Qian , Nougaret, Stephanie ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N1048

Impact of Neoadjuvant Therapy on Breast Conservation Rates in Triple- Negative and HER2-positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance)

Google Scholar

Golshan, Mehra , Cirrincione, Constance T. , Berry, Donald ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary Endpoint - Comprehensive Analysis - Breast - CALGB-40601 , CALGB-40603

Survival Outcomes from CALGB 80803 (Alliance): A Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy for Esophageal Cancer

DOI

Google Scholar

Goodman, Karyn A. , Hall, Nathan , Bekaii-Saab, Tanios , Ou, Fang-Shu ... - ASCO - J. Clin. Oncol. - 2018

Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-80803

Predictors of accrual success for cooperative group trials: The Cancer and Leukemia Group B (Alliance) experience

Google Scholar

Gordon, David , Liu, Qianying , Kleinman, Benjamin ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Health Outcome - Comprehensive

Phase III, randomized, double blind, placebo (P)-controlled trial of sorafenib (S) in desmoid tumor, (DT) (ALLIANCE A091105)

DOI

Google Scholar

Gounder, Mrinal M. , Mahoney, Michelle R. , Van Tine, Brian Andrew ... - ASCO - J Clin Oncol - 2018

Abstract - Primary Endpoint - Primary Analysis - Experimental - A091105

New lesions vs. growth of existing disease: does it impact prognosis?

Google Scholar

Grothey, A. , Heun, J. M. , Branda, M. , Goldberg, R. M. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N9741

Dual VEGF inhibition with sorafenib and bevacizumab (BEV) as salvage therapy in metastatic colorectal cancer (mCRC): results of the phase II North Central Cancer Treatment Group Study N054C

Google Scholar

Grothey, A. , Lafky, J. M. , Morlan, B. W. , Stella, P. J. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - GI - N054C

Associations of Insulin-Like Growth Factor Binding Proteins and Adiponectin with Disease Progression and Mortality in Metastatic Colorectal Cancer: Results from CALGB/SWOG 80405 (Alliance)

DOI

Google Scholar

Guercio, Brendan J. , Venook, Alan P. , Zhang, Sui , Ou, Fang-Shu ... - ASCO - J. Clin. Oncol. - 2019

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405

Relationship of opioid analgesic (OA) use at 3 months and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Google Scholar

Halabi, S. , Kelly, W. K. , Kaplan, E. B. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90401

A novel intermediate endpoint for predicting overall survival in men with metastatic castration-recurrent prostate cancer (CRPC)

Google Scholar

Halabi, S. , Ou, S. , Vogelzang, N. J. , Scher, H. I. ... - ASCO - J. Clin. Oncol. - 2007

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GU - Comprehensive

The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials.

Google Scholar

Halabi, Susan , Kelly, William Kevin , Zhou, Haojin ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GU - CALGB-90401 , S9916

A prognostic model for predicting overall survival in metastatic castrate-resistant prostate cancer (mCRPC) men treated with second-line chemotherapy

DOI

Google Scholar

Halabi, Susan , Lin, Chen-Yen , Small, Eric J. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90401

Randomized phase II trial of capecitabine and lapatinib with or without cixutumumab in patients with HER2+ breast cancer previously treated with trastuzumab and an anthracycline and/or a taxane: NCCTG N0733 (Alliance).

Google Scholar

Haluska, Paul , Bernath, Albert M. , Ballman, Karla V. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - Breast - N0733

Assessing the clinical significance of real-time Quality of Life (QOL) data in cancer patients treated with radiation therapy

Google Scholar

Halyard, M. Y. , Tan, A. D. , Callister, M. D. , Ashman, J. B. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Secondary Endpoint - Primary Analysis - Health Outcome - NCCTG-89-20-52

Evaluating the effect of tobacco on prostate cancer outcomes with VEGF-targeted therapy

Google Scholar

Harzstark, A. L. , Halabi, S. , Kelly, W. K. , Morris, M. J. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90401

Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).

Google Scholar

Hatch, Ace Joseph , Pang, Herbert , Starr, Mark D. , Brady, John C. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80203

Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405

Google Scholar

Heinemann, Volker , Niedzwiecki, Donna , Pearline, Rachel ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405

Randomized multicenter phase II trial evaluating the sequencing of PD-1 inhibition with pembrolizumab (ppembro) and standard platinum-based chemotherapy (chemo) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) AFT-09 (Alliance)

DOI

Google Scholar

Hensing, Thomas , Wang, Xiaofei , Kozono, David , Dudek, Arkadius ... - ASCO - J. Clin. Oncol. - 2019

Abstract - Primary Endpoint - Primary Analysis - Respiratory - AFT-09

A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB 90401 (Alliance)

Google Scholar

Hertz, D. L. , Owzar, K. , Halabi, S. , Kelly, W. K. , Zembutsu, H. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - C90401 , CALGB-60404

A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance).

Google Scholar

Hertz, Daniel Louis , Jiang, Chen , Owzar, Kouros , Halabi, Susan ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-60404 , CALGB-90401

CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer

Google Scholar

Himelstein, Andrew L. , Qin, Rui , Novotny, Paul J. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - CALGB-70604

Alliance A091104: A Phase II Trial of MK-2206 in patients with progressive, recurrent/metastatic adenoid cystic carcinoma

Google Scholar

Ho, Alan L , Foster, Nathan R. , Meyers, Jeffrey P. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - Experimental - A091104

Alliance A091404: a phase II study of enzalutamide (nsc# 766085) for patients with androgen receptor positive salivary cancers

DOI

Google Scholar

Ho, Alan Loh , Foster, Nathan R. , Zoroufy, Alex J. , Worden, Francis ... - ASCO - J. Clin. Oncol. - 2019

Abstract - Primary Endpoint - Primary Analysis - Experimental - A091404

Updated analysis of CALGB 100104: lenalidomide (Len) vs. placebo maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM).

Google Scholar

Holstein, Sarah A. , Owzar, Kouros , Richardson, Paul G. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Long-Term-Followup Analysis - Myeloma - CALGB-100104

Somatic DNA mutations, mutational load (ML), and MSI status: association with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance)

Google Scholar

Innocenti, Federico , Ou, Fang-Shu , Zemla, Tyler ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-80405

A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405

Google Scholar

Innocenti, Federico , Owzar, Kouros , Jiang, Chen ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-80405

A Genome-Wide Association Study (GWAS) Of Survival In Metastatic Breast Cancer (MBC) Patients Treated With Letrozole (L) With Or Without Bevacizumab (B) In CALGB 40503 (Alliance)

Google Scholar

Innocenti, Federico , Owzar, Kouros , Jiang, Chen ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-40503

NCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: A North Central Cancer Treatment Group study

Google Scholar

Jaeckle, K. A. , Schiff, D. , Anderson, S. K. , Galanis, E. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Primary Endpoint - Preliminary Analysis - Neuro-Onc - N0572

NCCTG (Alliance) N0572: A phase II trial of sorafenib and temsirolimus in recurrent glioblastoma (GBM) patients who progress following prior RT/temozolomide (TMZ) and VEGF inhibitors (VEGFi)

Google Scholar

Jaeckle, K. , Schiff, D. , Anderson, S. , Galanis, E. , Stella, P. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0572

Elderly patients with metastatic esophageal/gastric cancer: a pooled analysis of age-based outcomes from 8 consecutive North Central Cancer Treatment Group (NCCTG) therapeutic trials

Google Scholar

Jatoi, A. , Foster, N. R. , Egner, J. , Burch, P. , Stella, P. J. ... - ASCO - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - GI - N064C

A phase I/II trial adding the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib to induction carboplatin-paclitaxel in patients with locoregionally advanced squamous cell carcinoma of the head and neck (HNSCC) Alliance A091101

DOI

Google Scholar

Jelinek, Michael J. , Foster, Nathan R. , Zoroufy, Alex J. ... - ASCO - J Clin Oncol - 2018

Abstract - Primary Endpoint - Preliminary Analysis - Experimental - A091101

Combination of everolimus with R-CHOP (ever R-CHOP) as an initial therapy for diffuse large B cell lymphoma (DLBCL): NCCTG N1085 (Alliance) phase I and feasibility study

Google Scholar

Johnston, Patrick B. , LaPlant, Betsy R. , Nowakowski, Grzegorz S. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Preliminary Analysis - Lymphoma - N1085

Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101.

Google Scholar

Katz, Matthew H.G. , Shi, Qian , Ahmad, Syed , Herman, Joseph ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - GI - A021101

Alliance for clinical trials in oncology trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas

Google Scholar

Katz, Matthew , Herman, Joseph M. , Ou, Fang-Shu , Marsh, Robert ... - ASCO - J. Clin. Oncol. - 2017

Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - GI - A021501

Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts)

Google Scholar

Kelly, W. K. , Halabi, S. , Carducci, M. A. , George, D. J. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90401

Factors impacting oncologic outcomes after sublobar pulmonary resection: Results from ACOSOG Z4032 (Alliance), a randomized trial for high-risk operable non-small cell lung cancer (NSCLC)

Google Scholar

Kent, M. , Landreneau, R. , Mandrekar, S. , Nichols, F. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4032

North Central Cancer Treatment Group phase II study of panitumumab (Pmab), chemotherapy, and external beam radiation (Chemo-RT) in patients with locally advanced (LA) pancreatic cancer

Google Scholar

Kim, G. P. , Foster, N. R. , Haddock, M. G. , Dakhil, S. R. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Primary Endpoint - Primary Analysis - GI - N064A

Randomized phase II trial of panitumumab (P), erlotinib (E), and gemcitabine (G) versus erlotinib-gemcitabine in patients with untreated, metastatic pancreatic adenocarcinoma

Google Scholar

Kim, G. P. , Foster, N. R. , Salim, M. , Flynn, P. J. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Primary Endpoint - Primary Analysis - GI - N064B

Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU), and radiation therapy (RT) followed by gemicitabine (GEM) in patients with unresectable pancreatic cancer

Google Scholar

Kim, G. P. , Haddock, M. , Foster, N. R. , Bollinger, J. ... - ASCO - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Long-Term-Followup Analysis - GI - N0349

Phase II of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma

Google Scholar

Kim, G. P. , Oberg, A. L. , Foster, N. R. , Jaslowski, A. ... - ASCO - J. Clin. Oncol. - 2007

Abstract - Primary Endpoint - Primary Analysis - GI - N034A

Feasibility of geriatric assessment for older adults with acute myeloid leukemia (AML) receiving intensive chemotherapy on a cooperative group trial: CALGB 361006 (Alliance).

Google Scholar

Klepin, Heidi D. , Ritchie, Ellen K. , Sanford, Ben L. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - Older Adult - CALGB-361006

Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206

Google Scholar

Kluger, Harriet M. , Halabi, Susan , Solomon, Nicole C ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90206

Generation of adaptive HER2-specific immunity in HER2 breast cancer patients by addition of trastuzumab to chemotherapy in the adjuvant setting: NCCTG (Alliance) study N9831

Google Scholar

Knutson, K. L. , Perez, E. A. , Ballman, K. , Erskine, C. L. , Fox, N. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831

Associations of HER2-Specific Immunity with Survival During Treatment with Trastuzumab and Chemotherapy in Breast Cancer

Google Scholar

Knutson, Keith L. , Clynes, Raphael , Yeramian, Patrick ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N0337 , N98-32-52 , N0938

Tolerability of veliparib (V) in combination with carboplatin (C)/paclitaxel (P) - based chemoradiotherapy (CRT) in subjects with stage III non-small cell lung cancer (NSCLC).

Google Scholar

Kozono, David E. , Salama, Joseph Kamel , Stinchcombe, Tom ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Primary Endpoint - Primary Analysis - Respiratory - AFT-07

Veliparib (Vel) in Combination with Chemoradiotherapy (CRT) of Carboplatin/Paclitaxel (C/P) Plus Radiation in Patients With Stage III Non-Small Cell Lung Cancer (NSCLC) (AFT-07).

DOI

Google Scholar

Kozono, David E. , Stinchcombe, Thomas , Salama, Joseph K. ... - ASCO - J. Clin. Oncol. - 2019

Abstract - Primary Endpoint - Primary Analysis - Respiratory - AFT-07

Increasing Adherence to Adjuvant Hormone Therapy among Breast Cancer Patients: A Smart Phone App-Based Pilot Study

Google Scholar

Krok-Schoen, Jessica L. , Naughton, Michelle J. , Young, Gregory S. ... - ASCO - J Clin Oncol - 2018

Abstract - Primary Endpoint - Primary Analysis - Health Outcome - Pilot

Randomized Phase II Study of Everolimus Alone (E) versus Everolimus plus Bevacizumab (E+B) in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors, CALGB 80701 (Alliance)

Google Scholar

Kulke, Matthew H. , Niedzwiecki, Donna , Foster, Nathan R. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80701

A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER2 positive breast cancer

Google Scholar

Kutteh, L.A.. , Hobday, T. J. , Jaffe, A. S. , Laplant, B. R. ... - ASCO - J. Clin. Oncol. - 2007

Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831

Phase I randomized phase II trial of either dasatinib or placebo combined with standard chemoradiotherapy for newly diagnosed glioblastoma multiforme (GBM): Final results of phase I study

Google Scholar

Laack, N. N. , Galanis, E. , Leinweber, C. , Buckner, J. C. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Primary Endpoint - Preliminary Analysis - Neuro-Onc - N0877

Randomized Placebo-Controlled Phase II Study of Dasatinib with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma (GBM), N0877

Google Scholar

Laack, Nadia , Galanis, Eva , Anderson, S. Keith , Leinweber, Clinton ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0877

Circulating endothelial cells (CECs) in metastatic colorectal cancer (mCRC) patients treated with bevacizumab (BEV) and sorafenib

Google Scholar

Lafky, J. M. , Bot, B. M. , Morlan, B. W. , Anderson, S. K. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N054C

Association Between Patient Perception of Oncology Clinical Trial Participation and Survival: NCCTG N0392 (Alliance)

Google Scholar

Le-Rademacher, Jennifer , Dueck Amylou , Chauhan, Cynthia ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Health Outcome - NCCTG-N0392

Impact of Consensus Molecular Subtyping (CMS) on overall survival (OS) and Progression Free Survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance).

Google Scholar

Lenz, Heinz-Josef , Ou, Fang-Shu , Venook, Alan P. ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - CALGB-80405

Identifying Risk Factors For Toxicity In Patients With Hormone-Receptor Positive Advanced Breast Cancer Treated With Bevacizumab Plus Letrozole: A CALGB 40503 (Alliance) Correlative Study

Google Scholar

Li, Daneng , Dickler, Maura N. , McCall, Linda M. , Hahn, Olwen M ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary Endpoint - Primary Analysis - Older Adult - CALGB-40503

Body mass index (BMI), tumor subtype, and relapse-free survival (RFS) in CALGB 9741 (Alliance)

Google Scholar

Ligibel, J. A. , Cirricione, C. , Liu, M. , Citron, M. , Ingle, J. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Disparities - C9741

The Breast Cancer Weight Loss (BWEL) Trial: Randomized Phase III Trial Evaluating The Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer (Alliance A011401)

Google Scholar

Ligibel, Jennifer A. , Barry, William T. , Alfano, Catherine ... - ASCO - J Clin Oncol - 2018

Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - Breast - A011401

Semi-quantitative protein analysis of HER2 and ER levels in human breast cancer reveals broad expression ranges within HER2+ and ER+ phenotypes

Google Scholar

Liotta, L. , Pierobon, M. , Wulfkuhle, J. , Laird, J. , Livasy, C. ... - ASCO - J. Clin. Oncol. - 2009

Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007

Randomized phase II study comparing the met inhibitor cabozantinib to temozolomide (tmz) or dacarbazine (dtic) in ocular melanoma - A091201

Google Scholar

Luke, Jason J. , Allred, Jacob B. , Horvath, Laura E. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Preliminary Analysis - Experimental - A091201

A randomized phase ii study of anti-PD-1 antibody [MK-3475 (pembrolizumab)] alone versus anti-PD1 antibody plus stereotactic body radiation therapy in advanced merkel cell carcinoma (Alliance A091605)

DOI

Google Scholar

Luke, Jason , Chmura, Steven , Salama, Joseph , Al-Hallaq, Hania ... - ASCO - J Clin Oncol - 2018

Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - Experimental - A091605

Quality of life (QOL) for patients treated with FOLFOX+/-cetuximab (Cmab) following complete resection of colorectal cancer (CRC): Results from North Central Cancer Treatment Group (NCCTG) Phase III Trial N0147

Google Scholar

Mahoney, M. R. , Sloan, J. A. , Hubbard, J. M. , Liu, H. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0147

Are actual tumor measurements or categorical tumor response status better at predicting overall survival in cancer clinical trials?

Google Scholar

Mandrekar, M. D. , Hillman, S. L. , Campbell, M. E. , Hobbs, B. ... - ASCO - J. Clin. Oncol. - 2008

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - N9741

Impact of the Algorithm for Declaring Exact Progression Data on Progression-Free Survival Estimates in Advanced Lung Cancer

Google Scholar

Mandrekar, S. , Hillman, S. , Jatoi, A. , Jett, J. , Schild, S. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Secondary Endpoint - Primary Analysis - Respiratory - N0424

Impact of disease progression (DP) date determination method on post progression survival (PPS) and DP metrics in advanced lung cancer

Google Scholar

Mandrekar, Sumithra J. , Foster, Nathan R. , Qi, Yingwei ... - ASCO - J. Clin. Oncol. - 2012

Abstract - No-Endpoint Endpoint - Comprehensive Analysis - Respiratory - N0424

Improving the molecular risk classification for younger (<60 years) de novo cytogenetically normal acute myeloid leukemia (CN AML) patients (pts)

Google Scholar

Marcucci, G. , Maharry, K. S. , Whitman, S. P. , Paschka, P. ... - ASCO - J. Clin. Oncol. - 2009

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-20202 , CALGB-9621

A phase III randomized trial of intensive induction and consolidation chemotherapy +/- oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old

Google Scholar

Marcucci, G. , Moser, B. K. , Blum, W. G. , Stock, W. , Wetzler, M. ... - ASCO - J. Clin. Oncol. - 2007

Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10201

Evaluating the addition of bevacizumab (Bev) to endocrine therapy as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.

Google Scholar

Martin, Miguel , Loibl, Sibylle , Hyslop, Terry ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - CALGB-40503

CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma

Google Scholar

Martin, Peter , Jung, Sin-Ho , Johnson, Jeffrey L. , Pitcher, Brandy ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50803

CALGB/ECOG 100104 (Alliance) Study: Lenalidomide (LEN) vs Placebo (PBO) Maintenance (Maint) After Stem Cell Transplant (SCT) for Patients (Pts) With Multiple Myeloma: Overall Survival (OS) and Progression-Free Survival (PFS) Adjusted for Treatment (Tx) Crossover (XO)

Google Scholar

McCarthy, Philip L. , Holstein, Sarah A. , Jung, Sin-Ho ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Myeloma - CALGB-100104

Cellular transporter pharmacogenetics in metastatic colorectal cancer: Initial analysis of C80203

Google Scholar

Mcleod, H. L. , Owzar, K. , Kroetz, D. L. , Innocenti, F. , Das, S. ... - ASCO - J. Clin. Oncol. - 2008

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-80203

Pharmacogenetic dosing by UGT1A1 genotype as first-line therapy for advanced small-bowel adenocarcinoma: A North Central Cancer Treatment Group (NCCTG) trial

Google Scholar

Mcwilliams, R. R. , Mahoney, M. R. , Marchello, B. T. , Jatoi, A. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Primary Endpoint - Primary Analysis - GI - N0543

Impact of age and comorbidities on treatment effect, tolerance and toxicity in metastatic colorectal cancer (mCRC) patients treated on CALGB 80203

Google Scholar

Meyerhardt, J. A. , Jackson, N. A. , Niedzwiecki, D. , Hollis, D. R. ... - ASCO - J. Clin. Oncol. - 2009

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80203

Ratio of metastatic to examined lymph nodes is a powerful predictor of overall survival in rectal cancer: An analysis of Intergroup 0114

DOI

Google Scholar

Meyers, M. O. , Hollis, D. R. , Mayer, R. J. , Benson, A. B. 3rd ... - ASCO - J. Clin. Oncol. - 2007

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - C9081

Evaluation of the stage IB designation of the 7th edition of the AJCC staging system: Biologic factors are more important

Google Scholar

Mittendorf, E. , Ballman, K. , Mccall, L. , Hansen, N. , Lucci, A. ... - ASCO - Cancer Res. - 2012

Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z0010

A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second line therapy in advanced non-small cell lung cancer (NSCLC) of non-squamous histology: NCCTG N0626 study

Google Scholar

Molina, J. R. , Dy, G. K. , Foster, N. R. , Ziegler, Allen ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Primary Endpoint - Primary Analysis - Respiratory - N0626

A randomized double-blinded phase II study of the Seneca Valley Virus (NTX-010) vs placebo for patients with extensive stage SCLC (ES-SCLC) who were stable or responding after at least 4 cycles of platinum-based chemotherapy: NCCTG N0923 (Alliance) Study

Google Scholar

Molina, J. R. , Mandrekar, S. J. , Dy, G. , Aubry, M. C. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Respiratory - N0923

N0937 (Alliance): Final clinical results and correlative data from the phase II trial of cisplatin (C) and the novel agent brostallicin (B) in patients with metastatic triple-negative breast cancer (mTNBC)

Google Scholar

Moreno-Aspitia, A. , Liu, H. , Hillman, D. , Rowland, K. M. Jr ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Breast - N0937

Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer

Google Scholar

Moreno-Aspitia, Alvaro , Holmes, Eileen , Jackisch, Christian ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N063D

Randomized phase II pilot study of loratadine for the prevention of bone pain caused by pegfilgrastim.

Google Scholar

Moukharskaya, Julia , Abrams, Deborah Michelle , Khan, Farrah B. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - NCT01311336

Standard chemotherapy vs capecitabine for older women with early-stage breast cancer: Long-term results of CALGB 49907 (Alliance)

Google Scholar

Muss, Hyman B. , Berry, Donald A. , Cirrincione, Constance T. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Long-Term-Followup Analysis - Breast - CALGB-49907

Quality of life (QOL) and toxicity among patients in CALGB 80405

Google Scholar

Naughton, M. J. , Schrag, D. , Venook, A. P. , Niedzwiecki, D. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary Endpoint - Primary Analysis - Health Outcome - C80405

Genetic correlates of therapeutic toxicities of stage III colon cancer (CC) patients treated with adjuvant FOLFOX+/-cetuximab (Alliance NCCTG N0147)

Google Scholar

Newcomb, Polly A. , Sun, Wei , Hua, Xinwei , Banbury, Barbara ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary Endpoint - Primary Analysis - PPP - NCCTG-N0147

Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG 80405 (Alliance)

Google Scholar

Ng, Kimmie , Venook, Alan P. , Sato, Kaori , Yuan, Chen ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-80405

Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance)

Google Scholar

Nixon, A. B. , Halabi, S. , Shterev, I. , Starr, M. D. , Brady, J. C. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary Endpoint - Primary Analysis - GU - C90206

Blood-based biomarkers (BMs) in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI + bevacizumab (Bev), cetuximab (Cetux) or Bev + Cetux: Results from CALGB 80405

Google Scholar

Nixon, Andrew B. , Sibley, Alexander B. , Hatch, Ace J. ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - CALGB-80405

Phase II trial combining nab-paclitaxel (NP), gemcitabine (G) and bevacizumab (B) in patients (pts) with metastatic breast cancer (MBC): NCCTG N0735

Google Scholar

Northfelt, D. W. , Dueck, A. C. , Flynn, T. P. , Stella, P. J. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Primary Endpoint - Primary Analysis - Breast - N0735

Bendamustine and rituximab and lenalidomide (BRR) in the treatment of relapsed and refractory low grade non-Hodgkin lymphoma (NHL): Final results of phase 1 study NCCTG N1088/Alliance

Google Scholar

Nowakowski, Grzegorz S. , LaPlant, Betsy , Macon, William R. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - N1088

LE-SN38 for metastatic colorectal cancer after progression on oxaliplatin CALGB 80402

Google Scholar

Ocean, A. J. , Niedzwiecki, D. , Atkins, J. N. , Parker, B. A. ... - ASCO - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80402

Impact of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from CALGB 40601 (Alliance)

Google Scholar

Ollila, D. , Berry, D. , Cirrincione, C. , Carey, L. , Amos, K. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary Endpoint - Primary Analysis - Breast - C40601

Clinical course of patients with oxaliplatin-associated neuropathy: N08CB (Alliance)

Google Scholar

Pachman, Deirdre R. , Qin, Rui , Seisler, Drew K. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary Endpoint - Primary Analysis - Symptom Inter - N08CB

NCCTG N10C2 (Alliance): A double-blind, placebo-controlled study of magnesium supplements to reduce menopausal hot flashes

Google Scholar

Park, Haeseong , Qin, Rui , Smith, Thomas J. , Atherton, Pamela J. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N10C2

Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE).

Google Scholar

Patel, Jai Narendra , Jiang, Chen , Hertz, Daniel Louis ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90401 , CALGB-60404

Genome-wide association with survival in stage II-III colon cancer (CC) clinical trials (NCCTG N0147, Alliance for Clinical Trials in Oncology; NSABP C-08, NRG Oncology)

Google Scholar

Penney, Kathryn , Banbury, Barbara L. , Shi, Qian ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0147

The relationship between quantitative HER2 gene expression by the 21-gene RT-PCR assay and adjuvant trastuzumab (H) benefit in NCCTG (Alliance) N9831

Google Scholar

Perez, E. , Butler, S. , Dueck, A. , Baehner, F. , Jamshidian, F. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831

Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.

Google Scholar

Perez, Edith A. , Thompson, E. Aubrey , Anderson, S. Keith ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N9831

Alcohol consumption and prognosis in patients with stage III colon cancer: a correlative analysis of NCCTG phase III trial N0147

Google Scholar

Phipps, Amanda I. , Shi, Qian , Limburg, Paul J. , Nelson, Garth D. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary Endpoint - Primary Analysis - GI - N0147

First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).

Google Scholar

Piccart-Gebhart, Martine J. , Holmes, Andrew Peter , Baselga, Jose ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - Breast - N063D

Impact of poor prognostic features on the surgical treatment of breast cancer in an intergroup adjuvant chemotherapic trial

Google Scholar

Pockaj, B. A. , Dueck, A. , Tenner, K. ... - ASCO - J. Clin. Oncol. - 2007

Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831

Differences in psychosocial factors among diverse women enrolled in a phase III cooperative group metastatic breast cancer trial (CALGB 40502/Alliance)

Google Scholar

Polite, B. N. , Allred, J. B. , Rugo, H. S. , Cipriano, T. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Disparities - C40502

Incidence of bleeding and thrombosis among elderly patients undergoing systemic chemotherapy in advanced non-small cell lung cancer: An analysis of North Central Cancer Treatment Group trials

Google Scholar

Qi, Y. , Dy, G. K. , Nelson, G. D. , Schild, S. E. , Mandrekar, S. J. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Secondary Endpoint - Primary Analysis - Respiratory - N0424

Quality of Life Analysis of N0877 (Alliance): Phase II Trial of Either Dasatinib or Placebo Combined with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM)

Google Scholar

Qin, Rui , Tan, Angelina D. , Sloan, Jeff A. , Johnson, Derek Richard ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary Endpoint - Primary Analysis - Health Outcome - N0877

Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small cell lung cancer: A randomized, placebo controlled phase II study CALGB 30504 (ALLIANCE)

Google Scholar

Ready, N. E. , Pang, H. H. , Gu, L. , Otterson, G. A. , Thomas, S. P. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Respiratory - C30504

Effect of IGFIR protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG N9831 trial

Google Scholar

Reinholz, M. M. , Dueck, A. L. , Chen, B. , Geiger, X. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831

A Comparison of the Natural History of Oxaliplatin- and Paclitaxel-Induced Neuropathy (NCCTG N08C1, N08CB/Alliance)

Google Scholar

Ruddy, Kathryn Jean , Pachman, Dierdre , Qin, Rui , Seisler, Drew K. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - A151505 , N08C1 , N08CB

A Genetic Risk-Stratified, Phase II Study of Fludarabine/Antibody Combinations in Symptomatic, Untreated Chronic Lymphocytic Leukemia (CLL): Final Results of Cancer and Leukemia Group B (CALGB) 10404 (Alliance)

Google Scholar

Ruppert, Amy S. , Byrd, John C. , Heerema, Nyla A. , Smith, Mitchell ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10404

Serum Androgens and Survival in metastatic Castration Resistant Prostate Cancer (mCRPC) Patients Treated with Docetaxel and Prednisone: Results from CALGB 90401 (Alliance)

Google Scholar

Ryan, Charles J , Dutta, Sandipan , Kelly, William K ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90401

Questionable value of attribution when interpreting adverse event data: A joint evaluation by North Central Cancer Treatment Group (NCCTG) and American College of Surgeons Oncology Group (ACOSOG).

Google Scholar

SL, Hillman , DJ, Sargent , BM, Bot , RP, DeMatteo , EA, Perez ... - ASCO - J Clin Oncol - 2007

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - ACOSOG-Z9001

Interim analysis of CALGB 150607: A pilot project to study the expression of MET and p53 in resected lung adenocarcinoma specimens

Google Scholar

Salama, A. K. , Kratzke, R. A. , Richards, W. , Pang, H. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Secondary Endpoint - Preliminary Analysis - Correl Sci NOS - CALGB-150607

Clinical trial participants' strategies for coping with prescription drug costs: A companion study to CALGB 80405

Google Scholar

Schrag, D. , Naughton, M. J. , Kesselheim, A. , Archer, L. E. ... - ASCO - J. Clin. Oncol. - 2009

Abstract - Secondary Endpoint - Primary Analysis - Health Outcome - C80405

Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405.

Google Scholar

Schrag, Deborah , Dueck, Amylou C. , Naughton, Michelle Joy ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary Endpoint - Primary Analysis - Health Outcome - CALGB-80405 , CALGB-70502

Changing pattern for HER2 positivity due to updated ASCO/CAP guidelines for HER2 testing and its impact.

Google Scholar

Shah, Mithun Vinod , Wiktor, Anne E. , Meyer, Reid G. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N9831

A model-based approach to dose optimization of neurotoxic chemotherapy drugs for metastatic breast cancer (MBC)

Google Scholar

Sharma, Manish , Gray, Elizabeth , Mehrotra, Shailly , Wu, Kehua ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Breast - CALGB-40502

Lymph node (LN) ratio (LNR) risk classification (RC) in stage III colon cancer (CC): A pooled analysis of 16,425 patients from the ACCENT database.

Google Scholar

Shi, Q. , Hubbard, J. M. , Yothers, G. A. , Andre, T. , Saltz, L. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-N0441

Prospective pooled analysis of six phase III trials investigating duration of adjuvant oxaliplatin-based therapy (3 versus 6 months) for patients with stage III colon cancer: The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration (Alliance)

Google Scholar

Shi, Qian , Sobrero, Alberto , Shields, Anthony , Yoshino, Takayuki ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80702

Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: the IDEA collaboration

Google Scholar

Shields, Anthony F. , Ou, Fang-Shu , Paul, James ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80702

Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101

Google Scholar

Shulman, L. , Berry, D. , Cirrincione, C. , Becker, H. , Perez, E. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary Endpoint - Primary Analysis - Breast - C40101

Randomized phase II study of two doses of pixantrone in patients with metastatic breast cancer, N1031 Alliance.

Google Scholar

Sideras, K. , Moreno-Aspitia, A. , Tenglin, R. C. , Liu, H. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Primary Endpoint - Primary Analysis - Breast - NCCTG-N1031

Normative data and clinically significant effect sizes for single-item numerical linear analogue self-assessment (LASA) scales.

Google Scholar

Relationship between Metformin use and Recurrence and Survival in Patients (pts) with Resected Stage III Colon Cancer (CC) Receiving Adjuvant Chemotherapy: Results from NCCTG N0147 (Alliance)

Google Scholar

Singh, Preet Paul , Shi, Qian , Foster, Nathan , Grothey, Axel ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0147

Randomized Trial of FOLFOX Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability (ATOMIC, Alliance A021502)

Google Scholar

Sinicrope FA , Ou, F-S , Shi, Q , Nixon, A , Kabir Mody ... - ASCO - J. Clin. Oncol. - 2017

Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - GI - A021502

Molecular markers and survival after recurrence in stage III colon cancers from NCCTG N0147 and NSABP C-08 adjuvant chemotherapy trials

Google Scholar

Sinicrope, Frank A. , Shi, Qian , Allegra, Carmen Joseph ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0147 , NCCTG-N0147

Association of an immunoscore with survival of stage III colon cancer (CC) patients treated with adjuvant FOLFOX (Alliance N0147)

Google Scholar

Sinicrope, Frank A. , Shi, Qian , Hermitte, Fabienne , Heying, Erica ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - NCCTG-N0147

Validation of tumor infiltrating lymphocytes (TIL) and tumor budding as predictors of prognosis in patients with stage III colon cancers treated in a FOLFOX-based adjuvant therapy trial: NCCTG N0147 (Alliance)

Google Scholar

Sinicrope, Frank A. , Shi, Qian , Lee, Hee Eun , Foster, Nathan R. ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - N0147

Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy (NCCTG N0147) (Alliance)

Google Scholar

Sinicrope, Frank A. , Shi, Qian , Smyrk, Thomas C. ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - NCCTG-N0147

Molecular subtyping of colon cancers and distinct prognostic groups [NCCTG N0147 (Alliance)].

Google Scholar

Sinicrope, Frank A. , Shi, Qian , Thibodeau, Stephen N. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary Endpoint - Primary Analysis - GI - N0147

Association Of Tumor Infiltrating Lymphocytes (Tils) With Molecular Subtype And Prognosis In Stage III Colon Cancers From A FOLFOX-Based Adjuvant Chemotherapy Trial: NCCTG N0147 (Alliance)

Google Scholar

Sinicrope, Frank A. , Smyrk, Thomas C. , Foster, Nathan R. ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0147

Overall survival result and outcomes by KRAS, BRAF, and DNA mismatch repair in relation to primary tumor site in colon cancers from a randomized trial of adjuvant chemotherapy: NCCTG (Alliance) N0147.

Google Scholar

Sinicrope, Frank A. , Yoon, Harry H. , Mahoney, Michelle R. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary Endpoint - Primary Analysis - GI - N0147

Was it worth it (WIWI)? patient satisfaction with clinical trial participation: Results from North Central Cancer Treatment Group (NCCTG) Phase III Trial N0147

Google Scholar

Sloan, J. A. , Mahoney, M. R. , Sargent, D. J. , Hubbard, J. M. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Secondary Endpoint - Primary Analysis - Health Outcome - NCCTG-N0147

Relationship between genetic markers and quality of life (QOL) in stage III colon cancer (CC) patients (pts) prior to adjuvant treatment (N0147).

Google Scholar

Sloan, J. A. , Shi, Q. , Lee, A. , Diasio, R. B. , Pavey, E. S. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Health Outcome - NCCTG-N0147

Tumor burden is not related to quality of life in patients with metastatic colorectal cancer

Google Scholar

Sloan, J. , Grothey, A. , Green, E. , Zhao, X. , Campbell, M. ... - ASCO - J. Clin. Oncol. - 2008

Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N9741

Combining survival and toxicity effect sizes from clinical trials into an interpretable, quality-adjusted survival effect size estimate of treatment efficacy.

Google Scholar

Sloan, Jeff A. , Major, Brittny , Novotny, Paul J. , Grothey, Axel ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Symptom Inter - NCCTG-89-20-52

Detection of the BRAFV600E protein in human colon carcinomas by a mutation-specific antibody

Google Scholar

Smyrk, T. C. , Tougeron, D. , Thibodeau, S. N. , Singh, S. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0147

Sunitinib (S) switch maintenance in advanced non-small cell lung cancer (NSCLC): An ALLIANCE (CALGB 30607), randomized, placebo-controlled phase III trial.

Google Scholar

Socinski, Mark A. , Wang, Xiaofei F. , Baggstrom, Maria Quintos ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30607

Effects of age, immune landscape, and response to trastuzumab (H) in HER-2 positive (HER2+) breast cancer in NCCTG (Alliance)-N9831.

DOI

Google Scholar

Soyano, Aixa Elena , Serie, Daniel , Mashadi-Hossein, Afshin ... - ASCO - JCO - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N9831

An analysis of the prevalence of HER2 and KRAS mutations, and ALK rearrangements and clinical outcomes in Cancer and Leukemia Group B [CALGB (Alliance)] trial 30406 in advanced non-small cell lung cancer (NSCLC)

Google Scholar

Stinchcombe, T. E. , Sholl, L. M. , Wang, X. , Gu, L. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - C30406

Prognostic significance of initial clinical and molecular genetic features of acute promyelocytic leukemia (APL): Results from the North American Intergroup Trial, C9710

Google Scholar

Stock, W. , Moser, B. K. , Powell, B. L. , Appelbaum, F. , Tallman, M. ... - ASCO - J. Clin. Oncol. - 2007

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - C9710 , CALGB-8461 , CALGB-9665

Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials

Google Scholar

Taieb, Julien , Malicot, Karine Le ... - ASCO - J Clin Oncol - 2015

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - N0147

A phase I/randomized phase II study of MLN0128 vs. Pazopanib in patients with locally advanced/unresectable and/or metastatic sarcoma: Alliance A091304

Google Scholar

Tap, William , Mahoney, Michelle , Horvath, Elise ... - ASCO - J. Clin. Oncol. - 2016

Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - Experimental - A091304

Use of Remote Symptom Monitoring with Breast Cancer Survivors using Patient Reported Outcome Measures in mychart

DOI

Google Scholar

Terstriep, S. , Wacker, J. , Horner, C. Quinlan , Basch, E. ... - ASCO - JCO - 2019

Abstract - Primary Endpoint - Primary Analysis - ACS CCDRC - A23_Pilot2

Use of baseline quality of life (QOL) as compared with performance status (PS) as prognostic factors for overall survival (OS) in patients with metastatic colorectal cancer (mCRC)

Google Scholar

Turja, J. , Grothey, A. , Sargent, D. , Szydlo, D. , Zhao, X. ... - ASCO - J. Clin. Oncol. - 2008

Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N9741

American Cancer Society (ACS) Nutrition and Physical Activity Guidelines after colon cancer diagnosis and disease-free (DFS), recurrence-free (RFS), and overall survival (OS) in CALGB 89803 (Alliance)

Google Scholar

Van Blarigan, Erin L , Fuchs, Charles S. , Niedzwiecki, Donna ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-89803

25-hydroxyvitamin D levels and survival in patients with advanced pancreatic cancer (APC): Findings from CALGB 80303

Google Scholar

Van Loon, K. , Owzar, K. , Jiang, C. , Kindler, H. L. , Mulcahy, M. F. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - C80303

Validation of a 12-gene colon cancer recurrence score (RS) in stage II colon cancer (CC) patients (pts) from CALGB 9581

Google Scholar

Venook, A. P. , Niedzwiecki, D. , Lopatin, M. , Lee, M. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Secondary Endpoint - Primary Analysis - GI - C9581

Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results

PubMed

Google Scholar

Venook, A. , Niedzwiecki, D. , Hollis, D. , Sutherland, S. ... - ASCO - J. Clin. Oncol. - 2006

Abstract - Primary Endpoint - Preliminary Analysis - GI - CALGB-80203

Impact of primary (1º) tumor location on overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance)

Google Scholar

Venook, Alan P. , Niedzwiecki, Donna , Innocenti, Federico ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-80405

CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).

Google Scholar

Venook, Alan P. , Niedzwiecki, Donna , Lenz, Heinz-Josef ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80405

Primary (1°) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance)

Google Scholar

Venook, Alan P. , Ou, Fang-Shu , Innocenti, Federico ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-80405

A phase II study of pre- and post-operative gemcitabine and erlotinib plus pancreaticoduodenectomy (PD) for patients with resectable pancreatic ductal adenocarcinoma (PDAC): ACOSOG/ Alliance Z5041 Trial

Google Scholar

Wei, Alice Chia-chi , Ou, Fang-Shu , Shi, Qian ... - ASCO - J. Clin. Oncol - 2018

Abstract - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z5041

Influence of molecular alterations on site-specific (ss) time to recurrence (TTR) following adjuvant therapy in resected colon cancer (CC)

Google Scholar

Wilcox, Ryan E. , Shi, Qian , Sinicrope, Frank A. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary Endpoint - Primary Analysis - GI - N0147

Change in mammographic density with metformin use: A companion study to NCIC study MA.32.

Google Scholar

Wood, Marie E. , Qin, Rui , Le-Petross, Huong T. , Hwang, E Shelley ... - ASCO - J. Clin. Oncol. - 2013

Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - Breast - A211201

Influence of vitamin D (Vit D) on mammographic density (MD) and insulin like growth factor 1 (IGF1): results of CALGB (Alliance) 70806

Google Scholar

Wood, Marie , Seisler, Drew K. , Hsieh, Meng-Kang , Kontos, Despina ... - ASCO - J. Clin. Oncol. - 2018

Abstract - Primary Endpoint - Primary Analysis - Prevention - CALGB-70806

Deletions in HSP110 T17 and Patient Prognosis in Stage III Microsatellite Instable (MSI) Colon Cancers: Findings from CALGB 89803 and NCCTG N0147.

Google Scholar

Wu, Christina , Shi, Qian , Tomsic, Jerneja , Meyers, Jeffrey ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-89803 , NCCTG-N0147

Relationship between overall survival and progression-free survival for recent NCCTG glioblastoma multiforme trials

Google Scholar

Wu, W. , Galanis, E. , Buckner, J. C. , Jaeckle, K. A. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Neuro-Onc - Comprehensive

Racial differences in KRAS/BRAF mutation rates and survival in colon cancer (NCCTG N0147 [Alliance]).

Google Scholar

Yoon, Harry H. , Shi, Qian , Alberts, Steven R. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0147

CD3+ and CD8+ tumor-infiltrating lymphocyte (TIL) densities prognostically stratify DNA mismatch repair-deficient (dMMR) colon cancer patients (pts): NCCTG N0147 (Alliance)

Google Scholar

Yoon, Harry H. , Shi, Qian , Heying, Erica N. , Muranyi, Andrea ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - N0147

Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients treated with adjuvant FOLFOX + cetuximab in the PETACC8 and N0147 adjuvant trials.

Google Scholar

Zaanan, Aziz , Shi, Qian , Taieb, Julien , Alberts, Steven R. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0147

PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and Ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated REnal Cell CancEr (Alliance A031704)

Google Scholar

Zhang, Tian , Ballman, Karla , Choudhury, Atish , Chen, Ronald C. ... - ASCO - J Clin Oncol - 2019

Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - GU - A031704

Venlafaxine to prevent oxaliplatin-induced neuropathy?: A pilot randomized placebo-controlled trial.

Google Scholar

Zimmerman, Collin Thomas , Atherton, Pamela J. , Pachman, Deirdre R. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - NCT01611155